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Abstract 
Background: Epigenetic inactivation of O6‑methylguanine DNA‑methyltransferase (MGMT) is associated with 
increased sensitivity to alkylating chemotherapeutic agents in glioblastoma patients. The genetic background 
underlying MGMT gene methylation may explain individual differences in treatment response and provide a clue to a 
personalized treatment strategy. Making use of the longitudinal twin design, we aimed, for the first time, to estimate 
the genetic contributions to MGMT methylation in a Danish twin cohort.
Methods: DNA‑methylation from whole blood (18 monozygotic (MZ) and 25 dizygotic (DZ) twin pairs) repeated 
10 years apart from the Longitudinal Study of Aging Danish Twins (LSADT) were used to search for genetic and envi‑
ronmental contributions to DNA‑methylation at 170 CpG sites of across the MGMT gene. Both univariate and bivariate 
twin models were applied. The intraclass correlations, performed on cross‑sectional data (246 MZ twin pairs) from an 
independent study population, the Middle‑Aged Danish Twins (MADT), were used to assess the genetic influence at 
each CpG site of MGMT for replication.
Results: Univariate twin model revealed twelve CpG sites showing significantly high heritability at intake (wave 1, 
h2 > 0.43), and seven CpG sites with significant heritability estimates at end of follow‑up (wave 2, h2 > 0.5). There were 
six significant CpG sites, located at the gene body region, that overlapped among the two waves (h2 > 0.5), of which 
five remained significant in the bivariate twin model, which was applied to both waves. Within MZ pair correlation in 
these six CpGs from MADT demarks top level of genetic influence. There were 11 CpGs constantly have substantial 
common environmental component over the 10 years.
Conclusions: We have identified 6 CpG sites linked to the MGMT gene with strong and persistent genetic control 
based on their DNA methylation levels. The genetic basis of MGMT gene methylation could help to explain individual 
differences in glioblastoma treatment response and most importantly, provide references for mapping the methyla‑
tion Quantitative Trait Loci (meQTL) underlying the genetic regulation.
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Background
Glioblastoma (GBM) is the most common malignant 
brain tumor which is highly fatal as its five-year rela-
tive survival is only 6.8% [1, 2]. The current standard 
therapeutic management for newly diagnosed GBM is 
maximal safe surgical resection, followed by systematic 
radiotherapy combined with concomitant and adjuvant 
temozolomide (TMZ). The addition of TMZ to radio-
therapy has successively improved the long-time sur-
vival for GBM patients [3]. However, many of the GBM 
patients are insensitive to alkylating chemotherapeutic 
agents (e.g., TMZ) and thus cannot get benefit from the 
standard treatment [4].
One major cause is the silencing of the O6-methylgua-
nine DNA-methyltransferase (MGMT) gene [5–7]. The 
MGMT gene resides in chromosome 10q26 and encodes 
a DNA-repair enzyme [8, 9]. Aalkylating agents-induced 
cytotoxicity is triggered by adding its methyl group to 
specific sites, especially O6 positions of guanine. The 
O6-MeG adduct causes cell killing by inaccurate pairing 
of methylated guanine with thymine during DNA repli-
cation. The MGMT protein restores alkylation-induced 
DNA lesion by transferring the methyl group from the 
O6-MeG adduct to a cysteine residue in its active site 
irreversibly, thus blunts the therapeutic effect of alkylat-
ing agents [10, 11].
The silencing of the MGMT gene expression can be 
affected by both genetic and epigenetic factors [12, 13]. 
It is widely accepted that the MGMT promoter methyla-
tion is the leading regulation mechanisms which reduce 
gene expression. The study of the relationship between 
gene expression and the methylation patterns of the over-
all and specific CpG sites [14] in the promoter of MGMT 
has been a topic of wide interest [15]. Everhard et al. [16] 
found six CpG sites, which were located in the promoter 
region of MGMT, highly correlated with expression in 
GBMs. Bady et al. [17] identified two distinct regions in 
the CpG island of the promoter with high importance for 
MGMT silencing in GBM.
Though numerous studies have demonstrated that the 
MGMT promoter methylation status may determine 
the efficiency of TMZ treatment for the GBM patients 
[15–17], this biomarker has not yet been used in routine 
clinical practice to guide therapy for glioblastoma [18]. 
Methylation could also occur in the MGMT gene body. 
Gene body hypermethylation was positively correlated 
with MGMT expression in some GBM patients [19], 
which could partially explain the inconsistencies between 
the MGMT promoter methylation, gene expression level 
and different patient prognosis.
There are 176 CpG sites annotated for MGMT by 
HumanMethylation450 (450  k) beadchips. The total 
amount of discrete CpG methylation patterns, and intra-
tumoral methylation homogeneity of MGMT is variable 
in GBM [16, 20–22], and also other tumors [23]. In addi-
tion, Markus et  al. [24] reported that there is consider-
able variation of MGMT activity in normal tissues. These 
findings indicate that a degree of inter-individuals meth-
ylation heterogeneity and intra-individual variability 
exists.
DNA methylation is dynamic and changes through-
out the life course, while its levels are affected by envi-
ronmental factors, as well as genetic variation. Cis- or 
trans-acting genetic factors, known as methylation 
Quantitative Trait Loci (meQTL) can introduce or dis-
rupt CpG sites and have a significant effect on the meth-
ylation status of the specific gene. To our knowledge, 
genetic contribution or heritability in MGMT meth-
ylation is not well established and therefore, need more 
attention. Heritability is estimated by the correlation 
between genetic sharing and phenotypic sharing. Twin 
studies are regarded as the some of the best ways for 
assessing human heritability. Comparison of phenotype 
correlation in monozygotic (MZ) twin pairs who share 
their genetic makeups and dizygotic (DZ) twin pairs who 
share on average half of their genetic materials allows for 
better interpretation and quantification of genetic fac-
tors. Longitudinal twin studies on long term conserva-
tion of individual molecular phenotypes contribute to 
the exploration of genetic and environmental bases for 
maintaining molecular homeostasis [25–27]. This study 
introduces, for the first time, the twin design for disease 
studies to assess the genetic contribution to the molec-
ular phenotype of MGMT methylation to provide (1) 
reference for mapping meQTL of the MGMT gene; and 
(2) explanation to the observed individual differences in 
treatment response.
Methods
Study subjects and blood collection
The study samples were obtained from two independent 
surveys from the Danish Twin Registry, the Longitudinal 
Study of Aging Danish Twins (LSADT) launched in 1995 
and the Middle-Aged Danish Twins (MADT) conducted 
in 1998. Eighty-six Danish twins including 18 monozy-
gotic (MZ) and 25 dizygotic (DZ) like-sex pairs were 
collected by the LSADT. Blood samples were collected 
Keywords: MGMT, DNA methylation, CpG site, Twin models, Heritability, Glioma
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twice with a 10-year gap. The first wave blood samples 
were collected in 1997 with ages ranging from 73.21 to 
81.75 years. The second wave of blood samples was taken 
in 2007 [28]. A total of 246 monozygotic twin pairs, 
ranging in age from 55.94 to 79.88, were obtained from 
MADT [29]. Blood samples were collected during the 
follow-up visit in 2008–2011. Zygosity for LSADT was 
classified using highly polymorphic microsatellite mark-
ers, while zygosity for MADT was based on questions 
regarding physical similarity [30]. LSADT and MADT 
study design and data collection have previously been 
described in details elsewhere [29, 31, 32].
The study was conducted under approval by the Dan-
ish Scientific Ethics Committees and in agreement with 
the Helsinki II declaration. All participants in the surveys 
have given informed consent.
Genomic DNA extraction
DNA was extracted from buffy-coat from EDTA anti-
coagulant samples and converted with sodium bisulfite 
by the EZ-96 DNA-methylation kit (Zymo Research, 
Orange County, USA) following the manufacturer’s pro-
tocol [33]. Details of this process have been described by 
Tan et al [34].
Array‑based DNA methylation profiling
The measurement of genome-wide DNA-methylation 
was performed on the Infinium HumanMethylation450 
(450  k) beadchips (Illumina, San Diego, CA, USA) to 
obtain the DNA methylation level at 485,512 CpG sites 
spanning genes and CpG island regions of the human 
genome. Six pairs of twins were assayed together on the 
same chip. Subset-quantile Within Array Normaliza-
tion (SWAN) was performed to reduce technical bias 
between Type 1 and Type 2 probes by R package minfi 
[35]. Methylation level on each CpG site was calculated 
by the β value, defining as (the methylated allele inten-
sity) / (methylated + unmethylated allele intensity + 100). 
β value ranged from 0 to 1, indicating non methylation 
and 100% methylation respectively [36]. M value (logit 
of β value with base 2) was used in the following meth-
ylation analysis, which avoided the heteroscedastic disad-
vantage of β value [37].
Quality control (QC)
For each CpG site being interrogated, there are two site-
specific probes, one for methylated and the other for 
unmethylated loci to which chemically converted DNA 
is being hybridized. The detection P value, which is the 
proportion of background signal levels in samples for 
both methylated and unmethylated channels was used 
to control the probe quality. CpG probes with detection 
P value > 0.01 were regarded as missing. CpG probes 
harboring Single Nucleotide Polymorphisms (SNPs), and 
probes with > 5% missing values were excluded from the 
analysis. We used minfi to perform the quality control. 
After QC, a total of 176 CpGs on the array were linked to 
the MGMT gene. All CpG sites were annotated with the 
R package IlluminaHumanMethylation450kanno.ilmn12.
hg19 [38].
Estimating and adjusting cell composition
For each individual, we estimated cell composition based 
on six blood cell types (CD8T, CD4T, B cell, monocyte, 
granulocyte and natural killer cell) following the House-
man procedure. The residual values were used for fur-
ther analysis as the cell type composition was adjusted as 
covariates in the regression models [39].
Statistical analysis
In the discovery stage, using longitudinal data from 
LSADT, the correlation for each CpG site of MGMT in 
MZ and DZ twin pairs at two waves (1997 and 2007) 
were estimated by the intraclass correlations coefficients. 
Statistical significance for the difference of the correla-
tion by zygosity were tested based on Fisher’s z-test [40]. 
Heritability analyses of each CpG site of MGMT were 
conducted with two approaches: univariate twin analysis 
(Additional file  1: Fig.  S1 and Additional file  2: Fig.  S2) 
and bivariate twin analysis (Additional file  3: Fig.  S3). 
Meanwhile, cross-sectional data from MADT were used 
for replication purpose.
Twin modelling
Based on the polygenic biometric structural equation 
ADCE model, the methylation variation at each CpG site 
can be divided into four components, additive genetic 
(A), dominant genetic (D), common or shared environ-
mental (C) and unique environmental (E). Although 
both C and D variance components were included in the 
diagram (Additional file 1: Fig. S1 and Additional file 3: 
Fig. S3), they were confounded and cannot be estimated 
together [26, 27].
For the univariate twin analysis, we fitted full ACE and 
its nested models (AE, CE, and E), along with ADE and 
its nested models (AE, DE, and E) to methylation value of 
each of the 176 CpG sites. Goodness of fit of all models 
was evaluated by the Akaike information criteria (AIC) 
[41]. We first selected the best full model (BFM) between 
ACE and ADE models with the minimum AIC. Then we 
used the same way to get the best nested model (BNM) 
under the selected best full model. We applied the like-
lihood ratio test (LRT) which approximately follows 
the chi-squared distribution, to decide whether BFM or 
BNM was used. If the P value was > 0.05, we used BNM 
based on the principle of parsimony and testing whether 
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the components, A, C, D and E, are significantly greater 
than zero. Otherwise, we choose the model between BFM 
and BNM with the minimum AIC. After we got the best 
fitted model, the genetic component (A) was extracted 
and the corresponding heritability (h2) can be obtained 
by calculating the proportion of genetic variance among 
the total variance, i.e. h2 = A
A+C+E
 as narrow sense herit-
ability for the ACE model and h2 = A+D
A+D+E
 as broad sense 
heritability for the ADE model.
Secondly, we fit the bivariate twin model to investi-
gate the continuity of genetic influences at different time 
points (1997 and 2007 waves). The model analyses the 
genetic and environmental architecture of the covariance 
between two traits (methylation values at waves 1 and 2). 
MZ/DZ ratio of the cross-twin cross-traits covariances 
shows whether it is genetic or environmental factors that 
influence the traits [27]. The phenotypic (methylation 
value) within pair correlation is determined by genetic 
and environmental variance components similarly as in 
the univariate ADCE model.
In the univariate and bivariate twin models, MZ twin 
pairs correlate 1 for both additive (A) and dominant (D) 
genetic factors, whereas DZ twin pairs correlate 0.5 for 
A and 0.25 for D. Both MZ and DZ pairs correlate 1 for 
common environment (C), whereas unique environment 
(E) is uncorrelated in both types of twin pairs. In the 
bivariate twin model (Additional file 3: Fig. S3), rg, rd, rc, 
and re are the additive genetic, dominant genetic, shared 
environmental and unique environmental correlations on 
phenotype levels at the two time points, respectively. Age 
and sex were adjusted as covariates during the two-step 
analysis.
Replication
The significant CpGs with high heritability discovered 
from twin modelling were supposed to have high corre-
lation in MZ twin pairs. To reconfirm our findings, we 
calculated the intraclass correlations for each CpG site 
of MGMT to show the correlation level in MZ twin pairs 
from MADT.
All statistical analyses were performed using the R 
software (http://www.r-proje ct.org). The univariate and 
bivariate twin models were performed using the R pack-
age mets [42, 43] (https ://cran.r-proje ct.org/web/packa 
ges/mets/) and OpenMx [44] (https ://cran.r-proje ct.org/
web/packa ges/OpenM x/) respectively. Intraclass correla-
tion was estimated using the R package mets.
Results
Discovery stage
There were 16 monozygotic and 25 dizygotic twin 
pairs with complete information both in phenotype 
and methylation data from LSADT (Table  1). The pro-
moter regions of MGMT were defined as 1500  bp and 
200  bp upstream the transcription start site (TSS200 
and TSS1500). Six CpG sites (cg10502904, cg23004031, 
cg00198994, cg00657202, cg07638938 and cg26127080) 
were deleted due to missing values. Thus, 170 CpG sites 
(23 of promoter regions, 1 of 1st Exon and 5′ UTR, 144 
of gene body, 2 of 3′ UTR) were included in the following 
analysis.
Additional file 4: Table S1 shows the correlation for all 
CpGs of MGMT in MZ and DZ pairs at two time points 
separately. Overall, only 20 CpGs had significantly higher 
correlation for MZ twins than DZ twins in both 1997 and 
2007 (36 CpGs in 1997, 39CpGs in 2007), an indication of 
genetic influence in a small proportion of the total CpGs 
studied. For the gene body region, mean methylation 
Table 1 Descriptive characteristics for longitudinal twin samples from LSADT
MZ twins DZ twins All
Male Female Total Male Female Total
n, pair 6 10 16 5 20 25 41
Age, 1997
 Mean 76.97 76.13 76.45 76.79 76.05 76.19 76.29
 Median 76.67 75.61 76.31 75.85 75.68 75.71 75.79
 Min 75.21 73.21 73.21 74.66 74.05 74.05 73.21
 Max 79.51 81.75 81.75 79.32 79.59 79.59 81.75
Age, 2007
 Mean 86.82 86.04 86.33 86.55 85.86 86.00 86.13
 Median 86.27 85.25 85.97 85.95 85.60 85.68 85.73
 Min 85.23 83.30 83.30 84.13 84.00 84.00 83.30
 Max 89.53 91.70 91.70 89.13 89.49 89.49 91.70
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level had higher correlation for MZ twins than those for 
DZ twins, but with no significance in both waves. Simi-
lar pattern was applied to mean methylation level at pro-
moter region with P < 0.001 in 2007.
Univariate twin analysis
Additional file 5: Table S2 shows the process of how the 
final model was selected. After comparing the AIC of the 
two full models (ACE and ADE) and the corresponding 
nested models for each CpG site, as well as the mean of 
gene body and promoter regions, we found the best full 
and nested model. Then we did the likelihood ratio test 
(LRT) to decide the final best-fitted model. All the P val-
ues from comparison between best nested and best full 
model were no less than 0.05 in both two waves (1997 
and 2007), meaning all the final models were from a 
nested model (AE, CE, DE and E).
Additional file  6: Table  S3 describes the heritability 
of the best-fitted model derived from Additional file  5: 
Table S2. All CpG sites, as well as the mean of gene body 
and promoter regions in both waves were calculated. 
The heritability changed from 0 to nearly 1 (0.998 for 
cg09993319) in the 1997 wave and almost the same for 
the 2007 wave (the maximum was 0.996 for cg09993319). 
Table 2 describes the top significant 13 CpG sites in the 
two waves. In the 1997 wave, 12 CpG sites had signifi-
cantly high proportions of additive genetic covariance 
ranging from 0.428 (95% CI 0.004–0.852) for cg06179303 
to 0.998 (95% CI 0.997–1.000) for cg09993319 as their 
confidence interval did not include 0. This varied a lit-
tle in the 2007 wave as 7 CpG sites met that rule. There 
were 6 CpG sites (cg09993319, cg17686260, cg27275103, 
cg16255663, cg26201213 and cg06952798), which over-
lapped among the two waves. All 6 CpG sites had low 
to moderate unique environmental contribution to their 
total variation and low E components in their covariance 
at the two waves. As shown in Additional file 5: Table S2, 
all the 6 CpG sites are derived from AE model.
Table  3 shows 11 CpGs (cg03751055, cg25063211, 
cg07933035, cg12434587, cg26102564, cg18811130, 
cg12981137, cg02941816, cg13474692, cg02750154, 
cg18581292) with significant common environmental 
component overlapped between 1997 and 2007 rang-
ing from 0.358 (95% CI 0.069–0.648) for cg18581292 to 
Table 2 Heritability estimation at top 13 CpG sites of MGMT showing high heritability at two time points
a ,bRepresent significant CpG sites showing high heritability with 0 not included in the 2.5–97.5% confidence intervals in 1997 and 2007, respectively
c Represents overlapped significant CpG sites between 1997 and 2007
CpG site Year 1997 Year 2007
a2 c2 e2 a2 c2 e2
cg09993319c 0.9985 (0.9973–0.9997) 0.0000 (0.0000–0.0000) 0.0015 (0.0003–0.0027) 0.9961 (0.9931–0.9991) 0.0000 (0.0000–0.0000) 0.0039 (0.0009–
0.0069)
cg27275103c 0.9923 (0.9857–0.9990) 0.0000 (0.0000–0.0000) 0.0077 (0.0010–0.0143) 0.9853 (0.9740–0.9966) 0.0000 (0.0000–0.0000) 0.0147 (0.0034–
0.0260)
cg16255663c 0.9816 (0.9674–0.9958) 0.0000 (0.0000–0.0000) 0.0184 (0.0042–0.0326) 0.9760 (0.9575–0.9946) 0.0000 (0.0000–0.0000) 0.0240 (0.0054–
0.0425)
cg17686260c 0.9810 (0.9661–0.9960) 0.0000 (0.0000–0.0000) 0.0190 (0.0040–0.0339) 0.9874 (0.9776–0.9972) 0.0000 (0.0000–0.0000) 0.0126 (0.0028–
0.0224)
cg26201213c 0.7158 (0.4997–0.9320) 0.0000 (0.0000–0.0000) 0.2842 (0.0680–0.5003) 0.5978 (0.3148–0.8807) 0.0000 (0.0000–0.0000) 0.4022 (0.1193–
0.6852)
cg06952798c 0.5428 (0.2146–0.8711) 0.0000 (0.0000–0.0000) 0.4572 (0.1289–0.7854) 0.5033 (0.0980–0.9086) 0.0000 (0.0000–0.0000) 0.4967 (0.0914–
0.9020)
cg27483317a 0.7057 (0.4854–0.9261) 0.0000 (0.0000–0.0000) 0.2943 (0.0739–0.5146) 0.0000 (0.0000–0.0000) 0.5641 (0.2106–0.9176) 0.4359 (0.0824–
0.7894)
cg09757049a 0.5358 (0.1247–0.9469) 0.0000 (0.0000–0.0000) 0.4642 (0.0531–0.8753) 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–
1.0000)
cg10215460a 0.5175 (0.2026–0.8324) 0.0000 (0.0000–0.0000) 0.4825 (0.1676–0.7974) 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–
1.0000)
cg14668152a 0.5124 (0.2010–0.8237) 0.0000 (0.0000–0.0000) 0.4876 (0.1763–0.7990) 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–
1.0000)
cg14273607a 0.4750 (0.0226–0.9275) 0.0000 (0.0000–0.0000) 0.5250 (0.0725–0.9774) 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–
1.0000)
cg06179303a 0.4279 (0.0041–0.8516) 0.0000 (0.0000–0.0000) 0.5721 (0.1484–0.9959) 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–
1.0000)
cg02792401b 0.0000 (0.0000–0.0000) 0.0000 (0.0000–0.0000) 1.0000 (1.0000–1.0000) 0.5255 (0.0644–0.9866) 0.0000 (0.0000–0.0000) 0.4745 (0.0134–
0.9356)
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0.979 (95% CI 0.963–0.996) for cg03751055 (31 CpGs in 
year 1997, 27 CpGs in year 2007, respectively), from the 
results of Additional file 5: Table S2 and Additional file 6: 
Table S3.
Figure  1 shows the heatmap of heritability in all CpG 
sites. It shows the high genetic control is stable over time 
but moderate genetic control (yellow) disappeared after 
10  years. Figure  1 also suggests that there were CpGs 
constantly having substantial C component over the 
10  years. For mean methylation levels at promoter and 
gene body region, the heritability estimates were all 0 in 
both waves, but with significant common environment 
contributions (approximately 0.70) in both waves for 
gene body region and significant common environment 
component (0.641, 95% CI 0.417–0.865) only in year 
2007 for promoter region.
Table  4 shows the annotation information of the 
identified 6 CpGs with heritability. All the CpG sites 
Fig. 1 Heatmap of heritability in all CpG sites of MGMT 
Table 4 Annotation file of the significant CpG sites with high genetic control
a Position is for reference genome build hg19/GRCh37
b CpG-SNP corresponds to the SNPs present at the CpG interrogation
c MAF represents minor allele frequency, frequency of the second most frequent allele in 1000 Genomes European population. MAF of CpG-SNPs was obtained from 
Ensembl for hg19 (http://grch3 7.ensem bl.org/)
d Reference/Alternative alleles (Forward strand)
CpG site Gene (Name) Gene (Group) Positiona CpG‑SNPb Allelesd MAFc of CpG‑SNPs CpG Island 
(Name)
Relation_to_Island
cg06952798 MGMT Body 131,356,999 rs78877238 C/T 0.05(T) OpenSea
cg27275103 MGMT Body 131,477,739 rs77705384 C/T 0.14(T) OpenSea
cg16255663 MGMT Body 131,350,999 rs61859885 G/A 0.09(A) OpenSea
cg09993319 MGMT Body 131,529,435 rs7898151 G/A/T 0.47(G) OpenSea
cg17686260 MGMT Body 131,412,764 OpenSea
cg26201213 MGMT Body 131,265,796 chr10:131,264,948–
131,265,710
S_Shore
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were located in the gene body region. One CpG site, 
cg26201213 was in the CpG Island of S-Shore. Four 
CpG sites (cg06952798, cg16255663, cg09993319, and 
cg27275103) were CpG-SNPs, and minor allele frequen-
cies (MAFs) of these SNPs in the European population 
were all greater than 0.05.
Figure  2 shows the histogram and scatter plots for 
the beta values of the 4 CpG-SNPs significant in both 
waves. Obviously, the histograms for methylation 
levels of the 3 CpGs (cg09993319, cg27275103, and 
cg16255663) displayed triple peak patterns. The less 
obvious peaks for cg06952798 might be due to the MAF 
of the SNP is 0.05, too small to have sufficient people to 
have three genotypes in this small size sample. Figure 3 
shows the histogram and scatter plots for the 2 non 
CpG-SNPs significant in both waves. The histogram for 
cg26201213 showed a continuous pattern with a single 
peak. In contrast, there was a triple peak pattern for 
cg17686260. The scatter plots of MZ and DZ in both 
Figs.  2 and 3 indicated the methylation value changed 
a little during the 10 years. The scatter plot of the other 
164 CpG sites are shown in Additional file 7: Fig. S4.
Bivariate twin analysis
We next analyzed each CpG site by fitting the bivari-
ate twin model for the methylation measurements at 
the two waves. As shown in Additional file 8: Table S4, 
except for cg06952798, 5 of the 6 CpG sites remained 
significant during the bivariate analysis with very 
high genetic correlation (1.000) in methylation value 
between the two waves. Except for cg26201213, the 
unique environment had low correlation of the two 
times ranging from − 0.260 to 0.228. Additional file 9: 
Fig.  S5 shows the boxplot of covariance of additive 
genetic, shared environmental, dominant genetic, and 
unique environmental proportion.
Fig. 2 Histogram (a), scatter plot for MZ twins (b) and DZ twins (c) of the beta value for the 4 CpG‑SNPs which are significant in both waves. The 
scatter plots are symmetric by the twin1 = twin2 line, as each twin pair of the same wave was plotted twice
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Replication stage
There were 246 pairs of MZ twins in MADT cohort 
with 133 male twin pairs (54.07%). The median age was 
66.01. After QC, 172 CpGs were included, and the four 
dropped CpGs (cg00198994, cg00657202, cg07638938, 
cg26127080) overlapped with the dropped CpGs in 
discovery LSADT cohort. Figure  4 shows the correla-
tion coefficient plot of the MZ twin pairs. The above 
6 CpGs were all located at the upper left. Additional 
file  10: Fig.  S6 shows the histogram and scatter plots 
for the 6 CpGs. The patterns for each CpG remained 
the same as in the discovery stage.
Fig. 3 Histogram (a), scatter plot for MZ twins (b) and DZ twins (c) of the beta value for the 2 non CpG‑SNPs which are significant in both waves. 
The scatter plots are symmetric by the twin1 = twin2 line, as each twin pair of the same wave was plotted twice
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Discussion
Using longitudinal data from Danish twins, we have 
assessed, for the first time, how heritable and environ-
mental factors affect the variation in the DNA meth-
ylation level at individual CpG sites of the MGMT gene 
between two repeated measures spanning 10 years (from 
1997 to 2007). Univariate and bivariate twin models were 
fitted on each CpG site of MGMT in order to show their 
longitudinal changes. Our results highlight the important 
effect of genetic factors contribute to six specific CpG 
sites (cg09993319, cg2727510, cg16255663, cg06952798, 
cg17686260, and cg26201213, all located in the gene 
body region), with highest genetic factors accounting 
for over 99% (99.85% in 1997 and 99.61% in 2007) of 
total variance for cg09993319, and lowest genetic factors 
accounting for 60%-70% of total variance for cg26201213. 
Other 11 CpGs (cg03751055, etc.) constantly have sub-
stantial common environmental component over the 
10 years. The rest CpG sites, 90% of the whole CpG sites 
of MGMT, are not significantly heritable and explained 
solely by individual unique environment. All the findings 
we got were reconfirmed well in the younger population.
The estimated genetic components in MGMT meth-
ylation can pave the way for identifying the genetic vari-
ants underlying specific methylation site of MGMT. For 
example, genome-wide association studies (GWAS) can 
be performed to detect meQTLs with SNPs that regulate 
the methylation of CpG sites with high heritability. There 
have been many studies on the association between 
MGMT promoter CpG sites and glioma-related candidate 
SNPs [45, 46]. Rapkins et al. [47] reported the T allele of 
the rs16906252 promoter SNP has a significant role in 
the acquisition of MGMT methylation in GBM and is an 
indicator of response to temozolomide. Candiloro et  al. 
[48] showed that MGMT promoter methylation in the 
peripheral blood of normal individuals is strongly associ-
ated with the T Allele of the rs16906252 SNP. Xu et  al. 
[49] suggested that it is the MGMT haplotypes, instead of 
individual SNPs, which control MGMT transcription in 
healthy individuals and probably have a strong responsi-
bility in sensitivity to alkylating chemotherapeutic agents.
However, the reported meQTLs are mostly local 
and cis-regulated, instead of genome scale. As CpGs 
with high heritability estimates are mainly controlled 
by genetic factors, the six identified CpGs in this study 
can serve as important and valuable targets for efficient 
meQTL mapping using a GWAS approach to look for 
genetic variants that regulate the methylation levels of 
these CpGs through either cis- or trans-regulation in the 
genome, with the identified meQTLs as biomarkers for 
intervention purposes to improve individual treatment 
response in cancer patients.
Of the six identified CpGs with high heritability, 
four CpGs (cg09993319, cg2727510, cg16255663, and 
cg06952798) are CpG-SNPs, which means that there is 
a genetic variation across samples at this “C–G” loca-
tion. Most of them are major alleles with C/G. Because 
if the CpG-SNPs are very rare or minor allele, the meth-
ylation level will be low. Then we cannot estimate with 
power to detect this high heritability allele. The finding 
of CpG-SNPs as major heritable sites indicates that our 
twin modeling is capable of capturing methylation sites 
under genetic control. Meanwhile, the three peaks corre-
spond to each genotype. Considering the high heritability 
estimates for these CpGs, the methylation of these CpGs 
can be dependent on genotype as meQTL. Allele-specific 
methylation (ASM) at CpG-SNPs, which is one specific 
type of cis-meQTL, has been shown as an important 
mechanism through which genetic variation regulation 
function of a gene involving, for example, gene splicing 
[50] and genomic imprinting [51]. The detected CpGs 
with high heritability indicate individual genetic variation 
could regulate MGMT activity through ASM.
In contrast, two CpGs (cg17686260 and cg26201213) 
are not the CpG-SNPs. The histogram for cg17686260 
also shows a triple peak pattern. Considering the very 
high heritability estimates for this CpG (> 0.98), it can 
be highly likely that methylation of this CpG can be con-
trolled by an adjacent genetic variant as a cis-meQTL. If 
this is the case, mapping of relevant meQTLs can be done 
with ease with genetic variation data within the MGMT 
gene body region. After searching on UCSC (http://
genom e.ucsc.edu/) and Ensembl (http://grch3 7.ensem 
bl.org/) based on human genome hg19 reference, we 
found that there is one common SNP (rs61482214, ref-
erence/alternative alleles: G/–, MAF: 0.11) which located 
1 bp distance away from cg17686260.
Fig. 4 The correlation coefficient plot of MZ twin pairs. The 6 CpG 
sites, which are significant in both waves are shown in yellow
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The other CpG site, cg26201213, even is not the CpG-
SNP, still has high genetic control (0.6–0.7). The his-
tograms for the other CpG site, cg26201213, shows a 
continuous pattern with a single peak. Such a pattern 
could imply that the corresponding CpG is under control 
of multiple factors (here mainly genetic) potentially with 
both cis- and trans-meQTLs. Our finding can motivate 
for other study to perform GWAS to detect meQTLs 
with SNPs nearby or on other chromosomes that regu-
late the methylation of this CpG site. In sum, our twin 
modeling not only assesses the genetic contribution to 
site-specific DNA methylation, but also provides valuable 
information that can guide the meQTL mapping practice.
It is interesting that the CpGs under consistently high 
genetic control are all located in MGMT gene body. 
Gene body methylation is usually thought of as hav-
ing an opposite effect to promoter methylation for gene 
expression effect [52, 53]. The high genetic contribution 
to MGMT methylation in the gene body suggests that 
previous efforts on the genetics of MGMT methylation 
could have been biased toward the promoter region. In 
the literature, higher levels of gene body cytosine modi-
fication were correlated with higher MGMT expression 
levels, and also associated with glioblastoma treatment 
response [13, 19]. Combined with our results, more 
genetic association studies should be encouraged to look 
for genetic variants underlying gene body methylation 
and its clinical consequences. In the future, we aim for 
including glioblastoma patients to help to specifically 
clarify the direct roles of the detected CpGs for their clin-
ical implications.
The study has also found 11 CpGs with significant 
common environmental component. Epidemiology 
studies may help to explain how these CpGs are con-
stantly impacted by environmental factors (shared fam-
ily environment or early-life environment). Early-life 
environment are important for regulating methylation 
of these CpGs. It would be interesting to look for spe-
cific early-life environmental factors that are involved. 
This information can be useful for prevention and clinical 
intervention purposes.
Our study was advantaged by its design. First, the 
longitudinal design allowed us to compare and verify 
our parameter estimates between the two waves which 
helped us to reduce chance findings. Results from univar-
iate modeling at the two waves replicated each other to 
some degree, and were further verified by incorporating 
the classical twin method with longitudinal bivariate twin 
models. Second, to provide more stable and confident 
result, we looked at a much bigger cohort with MZ twins. 
We cannot calculate heritability of CpG sites. But if they 
had high genetic control, they should also have high cor-
relation in MZ twins. These six CpGs were on top after 
we ranked the ICC on methylation. It was somewhat 
reconfirmed that the estimation was stable and com-
pletely reliable.
Our study also has limitations. First, our sample size 
for discovery (16 MZ twin-pairs and 25 DZ twin-pairs) is 
not large. As a consequence, only CpGs with high genetic 
contribution were detected as significant. However, we 
replicated successfully in an independent cohort. Second, 
our findings are based on the genomic DNA from blood 
tissue and it is unclear whether these findings can be gen-
eralized to genomic DNA from other tissues, such as the 
cancer tissues. In the literature, Markus et  al. [24] had 
discussed that the MGMT expression level varies greatly 
in normal tissues and in some cases is associated with 
cancer predisposition. For a given individual, the expres-
sion level of MGMT was likely genetically determined. 
GWAS on DNA methylation levels of our identified her-
itable CpGs from the cancer tissues can help to verify our 
findings.
Conclusions
In summary, the application of classical twin models to 
the molecular phenotype of MGMT-methylation pro-
vides a novel approach for studying the contribution of 
genetics and environment to the epigenetic regulation of 
MGMT gene activity [54]. Results from our study, upon 
verification in tumor patients, not only help to explain 
the individual differences in treatment response in glio-
blastoma patients, but also provide efficient targets to 
meQTL mapping with aim for more effective personal-
ized cancer management tailored to specific needs, such 
as healthcare, prevention and treatment.
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